Awakn Life Sciences Corp. (AWKNF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. George Scorsis | Co-founder & Chairman of the Board | -- | -- | 1977 |
| Mr. Anthony Tennyson | Co-founder, President, CEO & Director | 174.17k | -- | -- |
| Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D. | Chair of Pre-Clinical & Clinical Advisory Board and Chief Research Officer | -- | -- | -- |
Awakn Life Sciences Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary Sketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available